Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin, Gazi University Faculty of Dentistry, Turkey

Prof. Dr. Sibel Elif Gültekin is a renowned academic and clinician in Oral Pathology and Periodontology at Gazi University Faculty of Dentistry, Türkiye. With over two decades of experience, she has significantly advanced molecular understanding of odontogenic tumors, HPV-induced oral lesions, and periodontal regeneration. Holding both DDS and Ph.D. degrees, she has led her department as Chair for 10 years and contributed globally as a visiting researcher and advisor. Her collaborations with institutions like the University of Cologne and UCSF reflect her international impact. She has published extensively in high-impact journals, authored books, and mentored numerous young researchers. Her dedication has been recognized through editorial appointments and professional society memberships. Prof. Gültekin’s translational research bridges pathology and clinical dentistry, making her a pioneer in the diagnosis and treatment of oral diseases.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Dual Specialization & Academic Leadership: Prof. Gültekin’s rare dual Ph.D. in Oral Pathology and Periodontology, along with her decade-long leadership as department chair, highlights deep academic and organizational expertise.

  2. High Research Output & Impact: With 96 publications, 50+ research projects, and citations exceeding 1300 (Google Scholar), her scholarly productivity and influence are clear. Her h-index across databases (14–17) confirms consistent academic contribution.

  3. Global Collaborations: Active collaborations with international centers like UCSF and University of Cologne underscore her role in global scientific advancement.

  4. Innovative Research Areas: She works at the forefront of molecular oncology, focusing on HPV-associated oral cancers, odontogenic tumors, and biomarkers like P16, VIM3, and PDCD4.

  5. Educational & Editorial Leadership: Served on scientific and editorial boards, symposiums, and advisory panels; she also authored 2 academic books and guided national congresses.

  6. Professional Societies: Active member of multiple esteemed societies (IAOP, ESP, EHNS, IADR), reflecting recognition in the international scientific community.

⚙️ Areas for Improvement:

  1. Clinical Translation Scaling: While her biomarker discoveries are notable, increasing efforts to lead translational clinical trials could accelerate therapeutic application.

  2. Policy Advocacy: Engaging more in international oral health policy or WHO-affiliated programs could amplify her impact beyond academia.

  3. Mentorship on Global Scale: Expanding formal international mentorship programs or fellowships could further cement her influence and legacy.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin holds both DDS and Ph.D. degrees, specializing in Oral Pathology and Periodontology. She completed her undergraduate dental studies at Gazi University Faculty of Dentistry, where she later pursued her doctoral studies. Her academic training extended beyond Türkiye through international fellowships and research placements, including the prestigious Department of Medicine and Stomatology at the University of California San Francisco (UCSF) and the Institute for Pathology at the University of Cologne. Her educational journey is marked by an interdisciplinary approach, blending basic sciences and clinical applications. These robust academic foundations have positioned her as a global expert in oral cancer biomarkers, regenerative periodontology, and molecular pathology, nurturing future dentists and researchers through an integrative, evidence-based curriculum and global research exposure.

💼 Experience:

Prof. Dr. Gültekin has over 25 years of experience in dentistry, oral pathology, and periodontology. She has served as Professor and Chair of the Department of Oral Pathology at Gazi University, shaping both academic curricula and national diagnostic standards. Internationally, she collaborated with UCSF and the University of Cologne on pioneering projects in oral cancer and HPV research. Her clinical and academic background spans over 50 funded research projects, with 96 published papers in prestigious journals indexed by SCI, Scopus, and PubMed. She has contributed to oral health policy through editorial and advisory roles, including at journals like Journal of Oral Health Frontiers. Her expertise has guided scientific boards and symposia in Türkiye and beyond, particularly in head and neck pathology. She remains a sought-after consultant and reviewer, advocating for personalized medicine and molecular diagnostics in oral health.

🔬 Research Focus:

Prof. Dr. Sibel Elif Gültekin’s research centers on the molecular mechanisms of oral diseases, particularly odontogenic tumors, oral epithelial dysplasia, and HPV-induced carcinomas. She has made key contributions in identifying biomarkers such as P16, PDCD4, VIM3, and CD8+ T-cell infiltrates, enhancing early diagnosis and prognosis of oral and oropharyngeal cancers. Her research also explores microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma. Additionally, she has contributed to periodontal tissue regeneration studies and the development of personalized therapeutic strategies. With over 1,300 citations and an h-index of 17 on Google Scholar, her impactful work bridges molecular science and clinical application. Collaborating with global experts in pathology, oncology, and molecular biology, Prof. Gültekin’s research not only contributes to academic literature but also informs clinical protocols and treatment pathways in modern dentistry and oral oncology.

📚 Publications Top Notes:

  • 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma (Genes, Chromosomes and Cancer, 2024)

  • 🧪 Efficiency of B-RAF-/MEK-inhibitors in B-RAF Mutated Ameloblastoma: Case Report and Review (Heliyon, 2023)

  • 🦷 Kişiselleştirilmiş Diş Hekimliği (ADO Klinik Bilimler Dergisi, 2023)

  • 🔍 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer (ADO Klinik Bilimler Dergisi, 2022)

  • 🛡️ PD-L1 Expression and High CD8+ Lymphocyte Infiltrate Predict Outcome in Oropharyngeal SCC (International Journal of Molecular Sciences, 2020)

🧾 Conclusion:

Prof. Dr. Sibel Elif Gültekin is a highly deserving nominee for the Best Researcher Award. Her pioneering contributions in oral pathology, particularly in molecular diagnostics and HPV-related oral oncology, place her at the forefront of dental research. Her exceptional academic record, leadership, and dedication to collaborative and translational science make her a standout candidate who embodies the spirit of innovation, mentorship, and global impact.

Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Posted on by sciencefather

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin , Gazi University Faculty of Dentistry , Turkey

Prof. Dr. Sibel Elif Gültekin is an accomplished academic and researcher in Oral Pathology and Periodontology at Gazi University, Ankara. With dual DDS and Ph.D. degrees, she has led the Department of Oral Pathology for a decade and significantly contributed to understanding oral cancer, odontogenic lesions, and HPV-related pathologies. Her collaborative research with institutions such as UCSF and the University of Cologne has yielded numerous high-impact publications and advancements in oral diagnostics. She has authored two books and published over 96 articles in reputable journals. A prominent figure in national and international research boards, Dr. Gültekin has also played a pioneering role in establishing oral pathology as a specialty in Türkiye. Her work integrates molecular biology with clinical oral health, emphasizing innovation, collaboration, and translational science. Recognized globally, she continues to mentor emerging scholars while contributing to policy-making and curriculum development in dental education.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Extensive Research Portfolio: Over 96 peer-reviewed publications, with 40 in SCI journals, reflects consistent scholarly productivity and scientific depth.

  • Citation Impact: High citation indices (Google Scholar: 1,381, h-index: 17) demonstrate strong academic influence and relevance in the field of molecular oral pathology.

  • International Collaborations: Long-term, productive collaborations with prestigious institutions including the University of Cologne and UCSF underline global recognition and trust.

  • Focused Expertise: Specialization in oral epithelial dysplasia, HPV-associated oral/oropharyngeal cancers, and molecular mechanisms of odontogenic lesions aligns closely with cutting-edge cell biology and translational research.

  • Academic Leadership: Established the Department of Oral Pathology in Türkiye and mentored future scientists, contributing to both academic infrastructure and talent development.

  • Editorial and Advisory Roles: Active roles in scientific boards and journals underscore her influence in shaping academic discourse and peer-review standards.

🛠 Areas for Improvement:

  • Patent Development: Incorporating translational research into patentable diagnostics or therapeutics would enhance practical impact and innovation scoring.

  • Funding & Industry Engagement: Broader engagement with industry-funded projects and clinical trials could further expand her work’s translational potential and outreach.

  • Global Clinical Guidelines Influence: Participation in international committees that develop clinical practice guidelines would strengthen policy-level impact.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin pursued her initial dental training and later earned dual Ph.D. degrees in Periodontology and Oral Pathology, demonstrating a unique interdisciplinary depth. She completed her undergraduate and doctoral education at Gazi University, Faculty of Dentistry, Ankara. Her academic journey also included prestigious international research fellowships at the University of Cologne (Germany) and the University of California, San Francisco (UCSF, USA), where she focused on advanced molecular mechanisms in oral diseases, especially HPV-related oncogenesis and tissue regeneration. Her training reflects a blend of clinical excellence and a strong foundation in molecular biology and translational research. Through a blend of local and global academic exposure, Dr. Gültekin has acquired cutting-edge knowledge and technical expertise, which she continues to leverage in her teaching and research. Her international education and academic credentials have contributed to building strong scientific bridges between Türkiye and the global dental research community.

🧪 Professional Experience:

Prof. Dr. Sibel Elif Gültekin has over 20 years of academic and research experience in dentistry, with a specialized focus on Oral Pathology and Periodontology. She currently serves as a full professor and head of the Oral Pathology Department at Gazi University Faculty of Dentistry, a position she has held for more than a decade. Dr. Gültekin has actively engaged in research collaborations with renowned institutions such as the University of Cologne and UCSF, significantly contributing to the fields of oral cancer and molecular diagnostics. She has completed over 50 research projects and advised numerous postgraduate theses. As a scientific advisor and board member for several national and international journals and associations, she plays a pivotal role in shaping academic and clinical standards. Her editorial appointments and leadership in symposia highlight her commitment to academic excellence and global research integration. She continues to lead innovation in oral health education and research policy.

🔬 Research Focus:

Dr. Gültekin’s research centers on the molecular pathology of oral diseases, with particular emphasis on oral epithelial dysplasia, HPV-induced oral/oropharyngeal cancers, and the genetic underpinnings of odontogenic tumors and cysts. Her studies have investigated biomarkers such as p16, PDCD4, and VIM3, enabling improved early detection and classification of oral malignancies. She is also involved in exploring microsatellite instability, loss of heterozygosity, and B-RAF/MEK inhibition in the context of oral and maxillofacial tumors. A major dimension of her work includes periodontal tissue regeneration and molecular mechanisms of tooth development, which bridges clinical periodontology with developmental biology. Her research is translational, aiming to bridge bench-to-chairside pathways, and supports the development of personalized diagnostic and therapeutic strategies. With over 1,300 citations and active involvement in global research initiatives, her investigations have significantly influenced current understanding and clinical approaches in oral pathology.

📄 Publications Top Notes:

  1. 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma – Genes, Chromosomes and Cancer (2024)

  2. 💊 Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review – Heliyon (2023)

  3. 🦷 Kişiselleştirilmiş Diş Hekimliği (Personalized Dentistry) – ADO Klinik Bilimler Dergisi (2023)

  4. 🧪 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer – ADO Klinik Bilimler Dergisi (2022)

  5. 🧫 PD-L1 Expression and CD8+ Lymphocyte Infiltration Predict Outcome in Oropharyngeal Squamous Cell Carcinoma – IJMS (2020)

🔍 Conclusion:

Prof. Dr. Sibel Elif Gültekin stands out as an exceptional and qualified candidate for the Best Researcher Award. Her work in the field of oral pathology and molecular diagnostics not only contributes to advancing science but also bridges basic research with clinical applications. With a solid foundation in interdisciplinary science, international collaboration, and academic leadership, she exemplifies the values the award seeks to honor. Her achievements strongly align with the criteria of sustained research excellence, innovation, and global impact.

Toru Kondo | Stem Cell Research | Best Researcher Award

Posted on by sciencefather

Prof. Toru Kondo | Stem Cell Research | Best Researcher Award

Prof. Toru Kondo , Hokkaido University , Japan

Dr. Toru Kondo is a distinguished researcher in molecular biology, specializing in stem cell biology, cancer research, and neurobiology. Currently, he serves as a professor at the Division of Stem Cell Biology at Hokkaido University, Japan. Dr. Kondo’s research primarily focuses on understanding the development and differentiation of neural stem cells, the molecular mechanisms behind glioblastoma, and cancer stem cells. He has made significant contributions to the field through groundbreaking studies on cellular reprogramming, stem cell fate, and cancer therapy. With an extensive publication record, Dr. Kondo’s work has influenced both academic research and clinical applications, especially in cancer therapy. Throughout his career, he has received numerous prestigious awards, such as the Human Frontier Science Program Fellowship and the Japanese Society for the Promotion of Science Fellowship.

Publication Profile: 

Scopus

Strengths for the Award:

  1. Exceptional Academic Background & Training: Dr. Kondo holds a Ph.D. in Molecular Biology from Osaka University, where he worked under the mentorship of Professor Yoshio Okada. His academic journey is complemented by positions at renowned institutions, such as the Osaka Bioscience Institute, University College London, and Kumamoto University, which highlight his international experience and versatility.

  2. Extensive Research Contributions: Dr. Kondo has made seminal contributions to the understanding of cell biology, particularly in stem cell biology and cancer research. His work on oligodendrocyte differentiation, cancer stem cells, and glioma-initiating cells is groundbreaking. Notably, he has explored reprogramming oligodendrocyte precursor cells into multipotent CNS stem cells and the molecular mechanisms of glioblastoma-initiating cell heterogeneity.

  3. Innovative Research on Cancer Stem Cells: His work on the persistence of cancer stem-like cells in glioma (2004) and the selective eradication of glioblastoma-initiating cells (2020) reflects a profound impact on the field of cancer biology. His research also addresses tumor cell-induced macrophage senescence and the role of gli2 in regulating neuroepithelial cells, which provide insights into tumor progression and therapeutic strategies.

  4. Leadership in Professional Organizations: Dr. Kondo’s active participation in organizations like the Japanese Cancer Association and the Japanese Association for Molecular Target Therapy of Cancer demonstrates his leadership and commitment to advancing cancer research and therapeutic development.

  5. Awards & Recognition: He has received prestigious awards, including the 1998 Human Frontier Science Program Long-Term Fellowship Award and the Japanese Society for the Promotion of Science Fellowship for Research Abroad. These accolades underscore his contributions and recognition by the international scientific community.

  6. Comprehensive Publication Record: With a long list of high-impact publications (over 15 selected research papers), Dr. Kondo’s work spans significant advancements in both stem cell biology and oncology. His research is frequently cited, indicating its relevance and influence in the scientific community.

  7. Impact on Stem Cell and Cancer Research: Dr. Kondo’s findings in cancer stem cell biology and differentiation processes contribute to broader biomedical applications, including cancer therapy, neural differentiation, and stem cell reprogramming. These areas are crucial for therapeutic development and have far-reaching implications for clinical interventions.

Areas for Improvement:

  1. Broader Public Engagement: While Dr. Kondo has made significant contributions to the scientific community, his outreach to the broader public, particularly regarding the practical applications of his research, could be expanded. Enhanced science communication efforts would help bridge the gap between research and public awareness.

  2. Collaborative Research Focus: Although Dr. Kondo’s work is influential, expanding his collaborations with other fields, such as bioinformatics, could further accelerate discoveries related to stem cell differentiation and cancer therapies. Additionally, a greater focus on collaborative interdisciplinary research could open new avenues for innovative therapies.

  3. Expanding Clinical Research Application: While his laboratory findings are groundbreaking, there could be more emphasis on translating these findings into clinical applications or clinical trial settings. Enhancing partnerships with clinical researchers and focusing on translational research may improve the direct impact of his work on patient outcomes.

Education:

Dr. Toru Kondo began his academic journey at Waseda University, where he earned a Bachelor of Science degree in 1988. He continued his studies at Osaka University, obtaining a Master of Science in Molecular Biology in 1990, under the guidance of Prof. Yoshio Okada. Dr. Kondo further pursued a Ph.D. in Molecular Biology at Osaka University, which he completed in 1994, again working under Prof. Okada. His doctoral research focused on the molecular mechanisms of cell death and immune responses. This strong academic foundation set the stage for his career, where he gained valuable postdoctoral experience at prestigious institutions such as the Osaka Bioscience Institute and the MRC Laboratory for Molecular Cell Biology in London. Dr. Kondo’s educational background laid the foundation for his profound contributions to stem cell biology and cancer research.

Experience:

Dr. Toru Kondo has held various prestigious academic and research positions over the years. He started as a Research Fellow at the Department of Molecular Biology at the Osaka Bioscience Institute (1994-1998), where he worked under Prof. Shigekazu Nagata. From 1998 to 2001, Dr. Kondo was a Research Fellow at the MRC Laboratory for Molecular Cell Biology in London, UK, collaborating with Prof. Martin C. Raff. His time in London also included a JSPS Research Fellowship for research abroad. In 2001, Dr. Kondo returned to Japan as an Associate Professor at the Institute of Molecular Embryology and Genetics at Kumamoto University, where he began his career in studying neural stem cells. Since 2007, Dr. Kondo has been a prominent figure in stem cell biology as a professor at Hokkaido University, contributing to groundbreaking research in cancer stem cells and neurobiology.

Awards and Honors:

Dr. Toru Kondo’s exceptional research has earned him numerous prestigious awards and fellowships throughout his career. Notably, in 1998, he was awarded the Human Frontier Science Program Long-Term Fellowship, which recognized his pioneering work in molecular biology. In the same year, he received the Japanese Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad. These awards provided critical support during his early career, enabling him to work at renowned international institutions, including the MRC Laboratory for Molecular Cell Biology in London. Dr. Kondo’s continued excellence in research has led to his election as a councillor in several professional organizations, including the Japanese Association for Molecular Target Therapy of Cancer and the Hokkaido Cancer Association. His dedication to advancing science and medicine has solidified his reputation as a leader in cancer and stem cell research.

Research Focus:

Dr. Toru Kondo’s research focuses on the molecular biology of stem cells, cancer stem cells, and neural differentiation. His work is centered on understanding the mechanisms behind stem cell fate determination and reprogramming, particularly within the context of neural cells and glioblastoma. Dr. Kondo has made groundbreaking contributions to the field of cancer research, especially in identifying cancer stem cells within gliomas and studying their role in tumor initiation and progression. His research has also advanced our understanding of how signaling pathways and chromatin remodeling influence cell differentiation. By studying the molecular networks involved in these processes, Dr. Kondo aims to uncover novel therapeutic targets for cancer treatment. His work on reprogramming oligodendrocyte precursor cells to multipotential neural stem cells and exploring cellular plasticity has also opened new avenues in regenerative medicine. His research holds promise for advancing personalized cancer therapies and stem cell-based treatments.

Publications Top Notes:

  1. Temperature-sensitive phenotype of a mutant Sendai virus strain is caused by its insufficient accumulation of the M protein. 🦠🔬
  2. Essential roles of the Fas ligand in the development of hepatitis. 🧬💉
  3. Activation of distinct caspase-like proteases by Fas and reaper in Drosophila cells. 🧬🐞
  4. The Id4 HLH protein and the timing of oligodendrocyte differentiation. 🧠🧬
  5. Basic helix-loop-helix proteins and the timing of oligodendrocyte differentiation. 🧠💡
  6. Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. 🔄🧬
  7. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. 🧠💥
  8. Negative regulatory effect of an oligodendrocytic bHLH factor OLIG2 on the astrocytic differentiation pathway. 🧠⚙️
  9. A role for Noggin in the development of oligodendrocyte precursor cells. 🧬🔬
  10. Nuclear export of OLIG2 in neural stem cells is essential for CNTF-induced astrocyte differentiation. 🧠💫
  11. Chromatin remodeling and histone modification in the conversion of oligodendrocyte precursors to neural stem cells. 🧬🧠
  12. Gli2 is a novel regulator of sox2 expression in telencephalic neuroepithelial cells. 🧠🌱
  13. Glioblastoma formation from cell population depleted of prominin1-expressing cells. 🧠💥
  14. Sox11 prevents tumorigenesis of glioma-initiating cells by inducing neuronal differentiation. 🧠💡
  15. Esophageal cancer-related gene 4 is a secreted inducer of cell senescence expressed in aged CNS precursor cells. 🧬🕰

Conclusion:

Dr. Toru Kondo’s career reflects excellence in molecular biology, stem cell research, and cancer biology. His academic background, leadership roles in professional societies, and exceptional body of work make him an ideal candidate for the Best Researcher Award. He has made substantial contributions to understanding the mechanisms of cell differentiation and cancer stem cell biology, which are pivotal for developing targeted therapies for cancer. His continued work will undoubtedly influence future advancements in regenerative medicine and cancer therapy.